This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
Y-27632, Dihydrochloride Salt (Y27, CAS 129830-38-2), >99%
Product information "Y-27632, Dihydrochloride Salt (Y27, CAS 129830-38-2), >99%"
Solubility: Soluble in DMSO at 160 mg/mL, soluble in ethanol at 12 mg/mL with warming, soluble in water at 90 mg/mL, buffers, serum, or other additives may increase or decrease the aqueous solubility. Y-27632 is a novel and specific Rho-associated coiled-coil forming protein kinase (ROCK) inhibitor. Narumiya, S., et al. 'Use and properties of ROCK-specific inhibitor Y-27632.' Methods Enzymol. 325: 273-284 (2000). This research compound is the dihydrochloride salt form of Y-27632. We also plan to offer the free base form, please see Y-27632, Free Base, Cat. No. Y-5399. Y-27632 inhibited ROCK-I (Ki = 0.22 µM) and ROCK-II (Ki = 0.30 µM) by competing with ATP for its binding to the kinase. Ishizaki, T., et al. 'Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.' Mol. Pharmacol. 57: 976-983 (2000). Y-27632 selectively inhibited Ca2+ sensitization of smooth muscle and blocked its contraction, prevented Rho-induced, p160ROCK-mediated formation of stress fibers in cultured cells, and dramatically lowered hypertension in several hypertensive rat models. Uehata, M., et al. 'Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.' Nature 389: 990-994 (1997). Y-27632 inhibited cell transformation mediated by RhoA and its guanine-nucleotide exchange factor (GEF). Sahai, E., et al. 'Transformation mediated by RhoA requires activity of ROCK kinases.' Curr. Biol. 9: 136-145 (1999). Y-27632 inhibited both Rho-mediated activation of actomyosin and invasive activity of rat MM1 hepatoma cells. Continuous delivery of Y-27632 largely prevented the dissemination of MM1 cells implanted into the peritoneal cavity of syngeneic rats. Itoh, K., et al. 'An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.' Nat. Med. 5: 221-225 (1999). Y-27632 blocked chemotactic peptide-induced development of cell polarity and locomotion, and inhibited myosin light chain phosphorylation with similar potency (ED50 = 0.5-1.1 µM). Niggli, V. 'Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration.' FEBS Lett. 445: 69-72 (1999). Y-27632 had antinociceptive properties, possibly by inhibition of Rho-kinase. Buyukafsar, K., et al. 'Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice.' Eur. J. Pharmacol. 541: 49-52 (2006). Y-27632 blocked the development of ischemia/reperfusion-induced acute renal failure, possibly by inhibiting myeloperoxidase activity in an early phase after reperfusion. Teraishi, K., et al. 'Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats.' Eur. J. Pharmacol. 505: 205-211 (2004). Y-27632 prevented intrahepatic metastasis of human hepatocellular carcinoma. Takamura, M., et al. 'Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.' Hepatology 33: 577-581 (2001). Y-27632 inhibited both of lysophosphatidic acid (LPA)- and fibronectin (FN)-induced migration and morphological change of rat ascites hepatoma (MM1) cells. It impaired LPA- and FN-evoked formation of focal adhesions and actin bundles and suppressed LPA- and FN-induced tyrosine phosphorylation of focal adhesion kinase and paxillin in MM1 cells. Imamura, F., et al. 'Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase.' Jpn. J. Cancer Res. 91: 811-816 (2000).
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information